Godlaw Kamwa, Local Journalism Initiative
According to the National Advisory Committee on Immunization (NACI), a single dose vaccine whose first 300,000 doses have been discontinued may be better suited for populations for whom it is more difficult to plan a second dose.
This applies to mobile populations or hard-to-reach people who cannot receive ribonucleic acid (mRNA) vaccines. The Federal Committee recommends this Janssen vaccine to people aged 30 and over, “who have no contraindications if a particular person does not want to wait to be offered an mRNA vaccine, and if the benefits outweigh the benefits. Risks “.
However, NACI continues to prioritize authorized COVID-19 mRNA vaccines due to the protection offered and the lack of reported issues.
“The mRNA vaccine is preferred because of the recently published safety data for mRNA vaccines in pregnant women and concerns about treating vaccine-induced immune thrombocytopenia (TTIV) in pregnant women if it were to occur after the vaccine was given. viral vector vaccine, ”the updated guidelines read.
These NACI guidelines are not binding on provinces and territories, which may apply their own approach to the immunization process.
“The risk of thrombosis does not depend on age, but the risk of complications from COVID-19 will vary depending on your age and the situation around you. Therefore, if you are in a province or region where there are many cases of COVID-19, it is imperative to get vaccinated earlier in order to get faster protection, ”explained the president of the federal committee.re Caroline Kwach at a press conference.
The first batch of 300,000 doses of Janssen vaccine arrived in Canada on 28 April. Their distribution has been halted due to a “drug substance” produced at the facility responsible for its manufacturing process in the United States.